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Abstract
Background: Chemotherapy is still a critical issue in the management of leishmaniasis. Until recently, pentavalent
antimonials, amphotericin B or pentamidine compounded the classical arsenal of treatment. All these drugs are toxic and
have to be administered by the parenteral route. Tamoxifen has been used as an antiestrogen in the treatment and
prevention of breast cancer for many years. Its safety and pharmacological profiles are well established in humans. We have
shown that tamoxifen is active as an antileishmanial compound in vitro, and in this paper we analyzed the efficacy of
tamoxifen for the treatment of mice infected with Leishmania amazonensis, an etiological agent of localized cutaneous
leishmaniasis and the main cause of diffuse cutaneous leishmaniasis in South America.
Methodology/Principal Findings: BALB/c mice were infected with L. amazonensis promastigotes. Five weeks post-infection,
treatmentwith15daily intraperitonealinjectionsof20 mg/kgtamoxifenwasadministered.Lesionandulcersizeswererecorded
and parasite burden quantified by limiting dilution. A significant decrease in lesion size and ulcer development was noted in
mice treated with tamoxifen as compared to control untreated animals. Parasite burden in the inoculation site at the end of
treatment was reduced from 10
8.560.7 in control untreated animals to 10
5.060.0 in tamoxifen-treated mice. Parasite load was also
reduced in the draining lymph nodes. The reduction in parasite number was sustained: 6 weeks after the end of treatment,
10
15.560.5 parasites were quantified from untreated animals, as opposed to 10
5.160.1 parasites detected in treated mice.
Conclusions/Significance: Treatment of BALB/c mice infected with L. amazonensis for 15 days with tamoxifen resulted in
significant decrease in lesion size and parasite burden. BALB/c mice infected with L. amazonensis represents a model of
extreme susceptibility, and the striking and sustained reduction in the number of parasites in treated animals supports the
proposal of further testing of this drug in other models of leishmaniasis.
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Introduction
Protozoan parasites of Leishmania genus are the etiological agents
of leishmaniasis, a disease distributed worldwide with a broad
spectrum of clinical manifestations according to the causative
species and immunological status of the host. Leishmaniasis
current therapy is mainly based on the systemic administration of
toxic pentavalent antimonials or amphotericin B, drugs with
several side effects, such as arrhythmia, nephro- and hepatotox-
icity. Additionally, emergence of Leishmania strains resistant to
antimonials has been reported [1],[2]. Recently, miltefosine has
been approved in India for the therapy of visceral leishmaniasis
[3], but its efficacy on the treatment of American cutaneous
leishmaniasis has been shown to be variable depending on the
causative species [4],[5],[6],[7]. Therefore, new alternatives for
the treatment of leishmaniasis are greatly needed.
In South America, Leishmania amazonensis is one of the causative
agents of localized cutaneous leishmaniasis and the most important
agent of diffuse cutaneous leishmaniasis (DCL), a devastating
disease with uncontrolled progression, characterized by multiple
skin lesions and vaste numbers of amastigotes. As a rule, there is no
satisfactory response to DCL treatment [8],[9].
We have previously shown that the antiestrogen tamoxifen, a drug
extensively used as a chemotherapeutic and chemopreventive agent
against breast cancer, presents leishmanicidal activity in vitro. This
drug has a direct leishmanicidal effect and it also shifts the pH of
parasitophorous vacuoles from acid to neutral, which in turn
heightens the drug effect on amastigotes. Tamoxifen concentrations
of approximately 10 mM inhibit 50% of L. amazonensis viability and
growth in vitro [10]. In the present study we demonstrate that L.
amazonensis-infected BALB/c mice treated with tamoxifen for 2 weeks
presented a significant reduction in lesion size and parasite burden.
Materials and Methods
The Ethics Committee that has approved this study is the Ethics
Committee for Animal Experimentation of the Instituto de
Cie ˆncias Biome ´dicas, University of Sa ˜o Paulo.
L. amazonensis promastigotes (MHOM/BR/1973/M2269) were
grown in Medium 199 (Sigma-Aldrich) supplemented with 10%
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at 25uC. Female BALB/c mice (4–5 week-old) were inoculated
with 5610
6 stationary-phase parasites at the base of the tail. Five
weeks after infection, mice were randomly assigned into
experimental groups (n=7–10). Treated groups received intra-
peritoneal injections of 30.4 mg tamoxifen citrate/kg/day (the
drug equivalent to 20 mg/kg/day tamoxifen) or 20 mg/kg/day
meglumine antimoniate (Glucantime) for 15 days. Tamoxifen
citrate was purchased from Sigma-Aldrich, USA; Glucantime was
a kind gift from Sanofi-Aventis. Stock solutions of tamoxifen were
prepared in saline every two days and stored at 4uC. Disease
progression was evaluated once a week by recording the average
diameter of the tail measured as the mean of tail base diameters in
horizontal and vertical directions) and the ulcer size, expressed as
the ulcer area in mm
2. Measurements were taken with a caliper
(Mitutoyo Corp., Japan). Body and uterus weights were also
registered. Animal experiments were repeated four times and were
approved by the Ethical Committee.
Parasite burden from infected tissue was quantified as described
previously [11]. Promastigotes differentiated from lesion amastigotes
were used on drug sensitivity assays while in the first passage in vitro.
Cellular viability was assessed by measuring the cleavage of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT; Sig-
ma-Aldrich) by metabolically active cells as described [12].
Data on lesion progression were analyzed for statistical
significance by using the non-parametric Mann-Whitney test
(GraphPad Prism 5 software). Results of limiting dilution assay
were analyzed based on two-tailed Student t test for paired samples
using the ELIDA software. A result was considered significant at
P,0.05.
Results
The treatment of L. amazonensis-infected BALB/c mice was
initiated 5 weeks post-infection, time when lesions were already
established and apparent. Mice were treated with 20 mg/kg/day
tamoxifen intraperitoneally for 15 days. No toxic effects were
detected during or after drug treatment. At the end of treatment,
the average body weight in animals treated with tamoxifen was
equivalent to values for the control group (untreated mice:
26.261.1 g; treated mice: 25.461.8 g) and the average weight
of uteri indicated no significant alteration between tamoxifen-
treated (0.1860.4 g) and untreated mice (0.2160.6 g). Figure 1A
shows the progression of lesion size in untreated versus tamoxifen-
treated mice. During and after tamoxifen administration we
observed that treated animals presented less swelling at the
infection site when compared to control animals. A statistically
significant difference between the average thickness of lesions of
untreated and tamoxifen-treated mice was evident on completion
of treatment, at week 7 post-infection (P,0.001) and remained
clear until the end of the experiment (week 13, P,0.01), when
control mice had to be euthanized. Macroscopical aspects of the
lesions are displayed in Figure 1B for untreated (left column) and
tamoxifen-treated animals (right column).
Since L. amazonensis infection in BALB/c mice normally evolves
from swelling at the infection site to an ulcerated lesion with loss of
tissue, the measurement of lesion thickness can be misleading at late
time-points. So, another criteria used for evaluating disease
progression was the appearance and enlargement of ulcers.
Tamoxifen treated mice showed a very significant delay in the
development of ulcers when compared with untreated mice
(Figure 1C).
Parasite burden in tamoxifen-treated animals was evaluated
immediately after the interruption of treatment (7 weeks after
infection) and 6 weeks later (13 weeks after infection). As shown in
Figure 2, a significant decrease on total parasite numbers per
lesion on tamoxifen-treated animals was observed in both time
points. At the end of the experiment, the average number of
parasites was reduced by at least 99.7% in treated groups, as
compared to untreated animals. These results were reproduced in
3 independent experiments.
In order to evaluate the activity of tamoxifen in parallel with a
standard drug, a fourth experiment was performed with groups of
10 mice treated with 20 mg/kg/day tamoxifen, 20 mg/kg/day
Glucantime or mock-treated with saline. Treatment was initiated
4 weeks after infection and carried on for 15 days with daily
intraperitoneal infections. As shown in Table 1, three weeks after
the end of treatment, there was no difference in the average size of
lesions between mock and Glucantime-treated mice. The group
that received tamoxifen showed a significant decrease in lesion
thickness. Parasite burden was determined for the lesion site,
draining lymph node and spleen. There was a significant reduction
in the numbers of parasites recovered from tamoxifen treated mice
as compared to mock or Glucantime groups both at the lesion and
lymph node. No parasites were recovered from the spleen in any of
the groups (Table 1). Therefore, tamoxifen proved to be more
effective in this experimental model than the standard drug.
Finally, we investigated whether parasites remaining in
tamoxifen treated groups were less sensitive to the drug. MTT
viability assays showed that tamoxifen’s activity against promas-
tigotes derived from parasites extracted from treated or untreated
mice remained unchanged with EC 50% of 11.561.1 and
12.862.8 mM, respectively. Therefore, remaining parasites did
not develop resistance to tamoxifen during treatment.
Discussion
Our data reveal a significant effect of tamoxifen in the reduction
of skin lesions caused by L. amazonensis in BALB/c mice.
Effectiveness was apparent not only as reduced swelling and
ulceration in treated animals but also as an important reduction in
parasite burden.
The experimental model of infection used in this study is one of
extreme susceptibility. BALB/c mice infected subcutaneously with
Author Summary
Leishmaniasis is an antropozoonotic disease with a wide
range of clinical manifestations. In humans, signs of
disease vary from skin and mucosal ulcers to enlargement
of internal organs such as the liver and spleen. The
unicellular parasite Leishmania amazonensis is able to
infect humans and cause localized or diffuse skin lesions.
The treatment for this disease is difficult, as it requires
prolonged and painful applications of toxic drugs that are
poorly tolerated. Therefore, a key area in leishmaniasis
research is the study of new therapeutic schemes and less
toxic drugs. The present report is based on the investiga-
tion of tamoxifen’s activity (a compound that has been in
clinical use since the 1970s for the treatment of breast
cancer) in the treatment of mice experimentally infected
with L. amazonensis. We observed that infected mice
treated with 20 mg/kg/day of tamoxifen for 15 days
showed a significant clinical and parasitological response,
with reduction in the size of lesions and ulcers and
decreased numbers of parasites. These promising results
pave the way for further testing of this drug as a new
alternative in the chemotherapy of leishmaniasis.
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followed by ulceration and loss of tissue simultaneous with the
appearance of methastasis at distant sites. The treatment did not
lead to sterile cure of lesions but Leishmania parasites have been
shown to remain present and viable, although in decreased
numbers, after treatment with antimonials in a variety of animal
models, as well as in humans. The lack of clinical or parasitological
response to Glucantime in L. amazonensis BALB/c infected mice
has been reported previously [13].
Furthermore, the timing for initiation of treatment can
significantly influence the disease outcome, as stressed by previous
studies [14]. Our experimental treatments were initiated 30–
35 days after mice infection, an interval of time that allowed the
establishment of disease and when infection sites were already
swollen and, in some animals, had started ulcerating. So, the data
shown here imply that the intraperitoneal administration of
tamoxifen resulted in a remarkable response to treatment. We are
currently evaluating tamoxifen’s efficacy in the treatment of other
models of cutaneous and visceral leishmaniasis. We have shown in
vitro that tamoxifen leishmanicidal effect is independent of the
estrogen receptor [10] and therefore it is unlikely that response to
treatment would be different in male or female mice. Indeed,
preliminary results obtained in Leishmania chagasi infected hamsters
show no gender-related effect on the anti-leishmanial response to
tamoxifen.
Apart from its direct leishmanicial activity, tamoxifen mode of
action in vivo could involve other pathways favouring ameliora-
tion of the infection. Tamoxifen has been reported to increase
synthesis of inducible nitric oxide synthase and production of nitric
oxide [15]. We did not detect differences in the accumulation of
nitrate on supernatants of L. amazonensis infected macrophages
treated or not treated with tamoxifen (data not shown).
Figure 1. Follow up of L. amazonensis infection in BALB/c mice treated with tamoxifen (TAM). A: Progression of lesion thickness
(mean6SD) in untreated (solid line) or TAM-treated (dotted line) mice. B: Macroscopical evaluation of lesions in untreated (left column) and TAM-
treated mice (right column) at week 13 post-infection. C: Mean and SEM of ulcer size recorded from untreated (black bars) and TAM-treated animals
(white bars). * P,0.005. Data represents one of three independent experiments. A and C: Horizontal grey bars indicate period of TAM administration
(n=10 per group from week 5 to 7 or n=8 per group after week 7).
doi:10.1371/journal.pntd.0000249.g001
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models [16]. This drug has been used in mice in a variety of doses
and administration schemes. The dosage employed in this study was
chosen based on previous reports showing that, in mice, daily
intraperitoneal injections of 25 to 100 mg/kg of tamoxifen resulted
in drug serum levels similar to those observed in patients [17].
This antiestrogen has been widely used for treatment and
prevention of breast cancer [18]. The most serious side effect
observed on clinical grounds is an increased risk for endometrial
cancer which appears after prolonged use. Effects observed in our
experiments suggest that antileishmanial therapy with tamoxifen
would not require extensive periods of treatment. We did not
detect changes in uterine weight in treated female mice, a well-
established parameter for evaluation of tamoxifen’s toxicity [19].
Tamoxifen administered at 40 mg/kg/day for 4 weeks has been
recently shown to impair bone growth in rats [20] raising concerns
on the application of this drug to treat leishmaniasis in children.
We are also investigating the effect of other selective estrogen
receptor modulators with different effects in bone metabolism, like
raloxifene, as antileishmanial drugs.
The potential value of tamoxifen for treating human leishman-
iasis needs further evaluation. To the best of our knowledge, this is
the first report of an in vivo investigation on tamoxifen’s efficacy
against Leishmania infection and points to a new alternative in the
treatment of leishmaniasis.
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Figure 2. Parasite burden after treatment with tamoxifen
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post-infection; empty symbols; n=2) or 6 weeks after interruption of
treatment (13 weeks post-infection; filled symbols; n=6). * P,0.0001.
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Table 1. Evaluation of disease progression and parasite
burden in L. amazonensis-infected mice 3 weeks after the end
of treatment.
Saline
Glucantime
(20 mg/kg/d)
a
Tamoxifen
(20 mg/kg/d)
Lesion thickness (mm)
b 4.060.2 4.160.2 3.660.1
Parasite burden Lesion site
c 10
5.460.7 10
8.360.8 10
3.060.1
Lymph node
d 10
3.760.7 10
5.361.2 10
2.060.1
Spleen nd
e nd nd
Spleen weight (g) 0.160.0 0.160.0 0.160.0
aequivalent to 5.4 mg Sb
V/kg/day.
bSaline vs Tamoxifen: P,0.05 and Glucantime vs Tamoxifen: P,0.005.
c, dSaline vs Tamoxifen and Glucantime vs Tamoxifen: P,0.05.
e(nd) not detectable.
doi:10.1371/journal.pntd.0000249.t001
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